Vaxxinity (VAXX) Stock Price, News & Analysis

Company Overview

Vaxxinity, Inc. is a clinical‐stage biotechnology company focused on the discovery, development and commercialization of active immunotherapies for the treatment and prevention of neurodegenerative diseases and related conditions. Established in 2016 as an independent entity spun out from the University of Texas Southwestern Medical Center’s Vaccine Development Center, Vaxxinity leverages proprietary vaccine platforms to stimulate the immune system against self‐antigens implicated in Alzheimer’s disease, Parkinson’s disease and other age‐related disorders.

The company’s pipeline includes synthetic peptide vaccines designed to elicit a targeted antibody response with durable immunogenicity. Lead candidates such as UB-311 for Alzheimer’s disease and AV-1980R for Parkinson’s disease have progressed through early clinical studies, demonstrating favorable safety profiles and measurable biomarker engagement. In addition, Vaxxinity is advancing preclinical programs for acute neurological conditions, including ischemic stroke and other central nervous system injuries. Beyond its neurology portfolio, the company has explored recombinant vaccine formulations for infectious diseases, leveraging its manufacturing capabilities and adjuvant technologies.

Headquartered in Dallas, Texas, Vaxxinity operates research and development sites in North America while engaging strategic partners and contract research organizations across Europe and Asia. The company is led by a management team with extensive experience in immunology and vaccine commercialization. Ross M. Mullen, M.B.A., serves as Chief Executive Officer and co-founder, guiding corporate strategy and clinical development, while scientific leadership is provided by experts in neuroimmunology and peptide chemistry. Vaxxinity’s multidisciplinary approach aims to address significant gaps in therapies for chronic and acute neurological disorders through scalable vaccine solutions.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.05
• 52-Week Range: N/A
• Volume: 220 shs
• Average Volume: 4,769 shs
• Market Capitalization: $13 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VAXX Stock Analysis - Frequently Asked Questions

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) issued its earnings results on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16).

When did Vaxxinity IPO?

Vaxxinity (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaxxinity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxxinity investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Rivian Automotive (RIVN), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 3/27/2023
• Today: 7/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VAXX
• CIK: 1851657
• Web: www.vaxxinity.com
• Phone: 254-244-5739
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,748,000
• Free Float: 45,553,000
• Market Cap: $13 thousand
• Optionable: Not Optionable
• Beta: -23.96